Paper Details

  1. Home
  2. Paper Details

Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience.

Author: AmiRonen Ben, AmitOdelia, AviviIrit, Ben-EzraJonathan, Beyar-KatzOfrat, GoldRonit, GutweinOdit, KedarRotem, OnYael Bar, PerryChava, PikovskyOleg, RamRon, ShashaDavid, WolachOfir

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the use of TPO receptor agonists for treating persistent cytopenia in patients receiving anti-CD19 CAR-T cell therapy. TPO receptor agonists were effective in resolving cytopenia in all six patients who received them. Further investigation into the use of these agents for treating cytopenia following CAR-T therapy is warranted.
Paper Details　
Original Abstract of the Article :
Anti CD-19 chimeric antigen receptor T (CAR-T) cells demonstrate effective early anti-tumor response; however, impaired hematopoietic recovery is observed in about 30% of patients with prolonged cytopenia appearing as an unmet need for optimal treatment. All adult patients given commercially availab...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00277-022-04889-6

データ提供：米国国立医学図書館（NLM）

Thrombopoietin Receptor Agonists for Treating Bone Marrow Aplasia

This study investigates the therapeutic landscape of bone marrow aplasia, a condition characterized by impaired hematopoietic recovery. The study explores the potential of thrombopoietin receptor agonists, such as eltrombopag and romiplostim, to treat bone marrow aplasia in patients who have received anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The researchers found that thrombopoietin receptor agonists were effective in treating bone marrow aplasia in these patients, suggesting a potential new avenue for managing this challenging side effect of CAR T-cell therapy.

Thrombopoietin Receptor Agonists: A Promising Treatment for Bone Marrow Aplasia

This study found that thrombopoietin receptor agonists were effective in treating bone marrow aplasia in patients who have received anti-CD19 CAR T-cell therapy. This is a significant finding, as bone marrow aplasia can be a serious side effect of CAR T-cell therapy. The study's findings suggest that thrombopoietin receptor agonists could be a valuable tool for managing this complication.

A New Oasis in the Desert of Bone Marrow Aplasia

This study offers a ray of hope for patients struggling with bone marrow aplasia. The research suggests that thrombopoietin receptor agonists could be a valuable tool for managing this challenging side effect of CAR T-cell therapy.

Dr.Camel's Conclusion

This study demonstrates the potential of thrombopoietin receptor agonists as a treatment for bone marrow aplasia in patients who have received anti-CD19 CAR T-cell therapy. The findings suggest that these agonists could play a crucial role in managing this complication, leading to improved outcomes for patients.

Date :
  1. Date Completed 2022-07-15
  2. Date Revised 2022-07-15
Further Info :

Pubmed ID

35731278

DOI: Digital Object Identifier

10.1007/s00277-022-04889-6

Related Literature

Article Analysis
・Effects of tisagenlecleucel injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.